WO2009053535A3 - Peptide vaccine for influenza virus - Google Patents

Peptide vaccine for influenza virus Download PDF

Info

Publication number
WO2009053535A3
WO2009053535A3 PCT/FI2008/050598 FI2008050598W WO2009053535A3 WO 2009053535 A3 WO2009053535 A3 WO 2009053535A3 FI 2008050598 W FI2008050598 W FI 2008050598W WO 2009053535 A3 WO2009053535 A3 WO 2009053535A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
influenza virus
hemagglutinin
influenza
peptide vaccine
Prior art date
Application number
PCT/FI2008/050598
Other languages
French (fr)
Other versions
WO2009053535A2 (en
Inventor
Jari Natunen
Jukka Hiltunen
Ritva Niemelae
Jari Helin
Olli Aitio
Original Assignee
Glykos Finland Oy
Jari Natunen
Jukka Hiltunen
Ritva Niemelae
Jari Helin
Olli Aitio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/FI2007/050577 external-priority patent/WO2008049974A2/en
Application filed by Glykos Finland Oy, Jari Natunen, Jukka Hiltunen, Ritva Niemelae, Jari Helin, Olli Aitio filed Critical Glykos Finland Oy
Priority to US12/739,796 priority Critical patent/US20110191867A1/en
Priority to EP08841911A priority patent/EP2296688A2/en
Priority to AU2008316397A priority patent/AU2008316397A1/en
Publication of WO2009053535A2 publication Critical patent/WO2009053535A2/en
Priority to PCT/FI2009/050357 priority patent/WO2009133249A1/en
Publication of WO2009053535A3 publication Critical patent/WO2009053535A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides peptide epitopes for use in the prevention and/or treatment of influenza or for the development of such treatment or vaccine against influenza. The invention also relates to a method for evaluating the potential of a chemical entity, such as an antibody, to bind to a peptide epitope derived from the divalent sialoside binding site of hemagglutinin protein of influenza virus, and to conjugates containing one or more such peptide epitopes. The peptide epitopes of the invention are cyclic peptides comprising a 7-mer peptide derived from H1, H3 or H5 hemagglutinin of influenza virus. The 7-mer peptide has a sequence corresponding to the loop sequence at positions 220- 226 of X31-hemagglutinin.
PCT/FI2008/050598 2006-10-26 2008-10-24 Peptide vaccine for influenza virus WO2009053535A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/739,796 US20110191867A1 (en) 2006-10-26 2008-10-24 Peptide vaccine for influenza virus
EP08841911A EP2296688A2 (en) 2007-10-26 2008-10-24 Peptide vaccine for influenza virus
AU2008316397A AU2008316397A1 (en) 2006-10-26 2008-10-24 Peptide vaccine for influenza virus
PCT/FI2009/050357 WO2009133249A1 (en) 2008-05-02 2009-05-04 Peptide vaccine for influenza virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FIPCT/FI2007/050577 2007-10-26
PCT/FI2007/050577 WO2008049974A2 (en) 2006-10-26 2007-10-26 Peptide vaccine for influenza virus

Publications (2)

Publication Number Publication Date
WO2009053535A2 WO2009053535A2 (en) 2009-04-30
WO2009053535A3 true WO2009053535A3 (en) 2009-07-23

Family

ID=40585511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2008/050598 WO2009053535A2 (en) 2006-10-26 2008-10-24 Peptide vaccine for influenza virus

Country Status (2)

Country Link
EP (1) EP2296688A2 (en)
WO (1) WO2009053535A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658180B2 (en) 2008-08-15 2014-02-25 Mark A. Miller Vaccines against influenza virus
ES2731636T3 (en) * 2011-03-11 2019-11-18 Km Biologics Co Ltd Adjuvant composition containing citrulline

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998059244A1 (en) * 1997-06-20 1998-12-30 Eclagen Limited Identification of mhc binding peptides
US20020183484A1 (en) * 1998-10-09 2002-12-05 Torres Jose V. Immunogenic formulation and process for preparation thereof
WO2005037187A2 (en) * 2003-10-20 2005-04-28 Glykos Finland Oy High affinity ligands for influenza virus and methods for their production
WO2006111616A1 (en) * 2005-04-20 2006-10-26 Glykos Finland Oy Peptide vaccine for influenza virus
WO2006128294A1 (en) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation
WO2007122388A2 (en) * 2006-04-13 2007-11-01 Midatech Limited Nanoparticles containing three various ligands for providing immune responses against infectious agents
WO2008039267A2 (en) * 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2008049974A2 (en) * 2006-10-26 2008-05-02 Glykos Finland Oy Peptide vaccine for influenza virus
WO2008138120A1 (en) * 2007-05-11 2008-11-20 University Of Manitoba Avian influenza h5n1 hemagglutilin pseudotyped lentiviral vector system for rapid identification of antivirals and neutralizing polypeptides

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998059244A1 (en) * 1997-06-20 1998-12-30 Eclagen Limited Identification of mhc binding peptides
US20020183484A1 (en) * 1998-10-09 2002-12-05 Torres Jose V. Immunogenic formulation and process for preparation thereof
WO2005037187A2 (en) * 2003-10-20 2005-04-28 Glykos Finland Oy High affinity ligands for influenza virus and methods for their production
WO2006111616A1 (en) * 2005-04-20 2006-10-26 Glykos Finland Oy Peptide vaccine for influenza virus
WO2006128294A1 (en) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation
WO2007122388A2 (en) * 2006-04-13 2007-11-01 Midatech Limited Nanoparticles containing three various ligands for providing immune responses against infectious agents
WO2008039267A2 (en) * 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2008049974A2 (en) * 2006-10-26 2008-05-02 Glykos Finland Oy Peptide vaccine for influenza virus
WO2008138120A1 (en) * 2007-05-11 2008-11-20 University Of Manitoba Avian influenza h5n1 hemagglutilin pseudotyped lentiviral vector system for rapid identification of antivirals and neutralizing polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GELDER C. ET AL.: "Six unrelated HLA-DR-matched adults recognize identical CD4+ T cell epitopes from influenza A hemagglutinin that are not simply peptides with high HLA-DR binding affinities", INTERNATIONAL IMMUNOLOGY, vol. 10, no. 2, 1998, pages 211 - 222, XP003002111 *
GERHARD W. ET AL.: "Identification of Eight Determinants in the Hemagglutinin Molecule of Influenza Virus A/PR/8/34 (H1N1) Which Are Recognized by Class II-RestrictedT Cells from BALB/c Mice", JOURNAL OF VIROLOGY, vol. 65, no. 1, 1991, pages 364 - 372, XP003002112 *

Also Published As

Publication number Publication date
WO2009053535A2 (en) 2009-04-30
EP2296688A2 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
CY1119789T1 (en) CGRP ANTIBODIES
WO2010010466A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
ATE404225T1 (en) RADIOFLUORINATED PEPTIDES
CL2015001314A1 (en) Tau binding antibody; vector; host cell; hybridoma; peptide comprising epitope of tau; pharmaceutical composition comprising the antibody or tau peptide; medical device to administer them; and use to treat, prevent or diagnose Alzheimer's disease or related tautology (div. sol. No. 679-14).
EP3210625A3 (en) Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
WO2007089753A3 (en) Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
WO2008121615A3 (en) Antibody formulation
EA200802170A1 (en) LYOPHILIZED COMPOSITION OF THERAPEUTIC PEPTIDE ANTIBODY
MY157359A (en) Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
DE602004025101D1 (en) HUMAN ANTI-HUMANE CD3 BONDING MOLECULES
UA107490C2 (en) TNF-a-BINDING PROTEINS
NO20085362L (en) High-affinity human and humanized anti-alpha5 beta1-integrin function blocking antibodies with reduced immunogenicity
NO20081124L (en) Anti-CD 3 antibody formulations
WO2014134561A3 (en) Quantification of vaccine compositions
WO2011063235A3 (en) Peptides, devices, and methods for the detection of ehrlichia antibodies
WO2010002478A3 (en) Glycopeptide and uses thereof
UA113623C2 (en) TISSUE FACTOR FACTOR (TFPI) MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
ECSP10010327A (en) PEPTIDES OF FVIII AND ITS USE FOR TOLERANT HEMOPHYLICS
WO2009035412A8 (en) Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof
WO2012069433A3 (en) Antigen binding proteins to oncostatin m (osm)
DE602008005857D1 (en) NEW ANTIMALARIA VACCINE COMPOSITIONS AND APPLICATIONS THEREOF
WO2009053535A3 (en) Peptide vaccine for influenza virus
WO2014072958A8 (en) Peptides
WO2010009856A3 (en) Goodpasture antigen binding protein and its detection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08841911

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12739796

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008316397

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3600/DELNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008316397

Country of ref document: AU

Date of ref document: 20081024

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008841911

Country of ref document: EP